Literature DB >> 12639220

Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant role for polymorphic position - 107, implicating the Sp1 transcription factor.

Sara Deakin1, Ilia Leviev, Marie-Claude Brulhart-Meynet, Richard W James.   

Abstract

Accumulating data suggest that paraoxonase-1 (PON1) is a primary determinant of the antioxidant and anti-inflammatory capacities of high-density lipoproteins (HDLs). Variations in HDLs and PON1 have been shown to influence the functions of both. There is a wide spectrum of serum PON1 mass in humans, to which promoter polymorphisms make an important contribution. The present studies attempted to define: (i) the relevance in vivo of promoter polymorphisms by analysing haplotype structure; and (ii) molecular mechanisms implicated in promoter activity. Highly significant differences (P <0.0001) in serum mass and activity were observed as a function of haplotype sequence. Of three promoter polymorphisms (-107, -824 and -907), the -107 site was shown to be of predominant importance to serum PON1. Significant increases in serum PON1 mass and activities between haplotype subgroups could be explained by unit increases in the number of high-expresser variants of the -107 site (-107C) alone. No significant contribution was observed for the -824 and -907 sites. The coding-region Leu(55)-->Met (L55M) polymorphism made an independent contribution to serum PON1 mass, which may account for variations in serum PON1 mass and activity within haplotype subgroups defined by the -107 site. A molecular basis for the effect of the -107 polymorphism on serum PON1 was indicated by the greater affinity of the high-expresser variant (-107C) for hepatocyte nuclear extracts, indicating higher affinity for transcription factors. Competition studies with oligonucleotides representing the consensus (and mutated) sequence for Sp1, and the use of Sp1 antibodies, confirmed formation of complexes between the transcription factor and the PON1 promoter during incubation with nuclear extracts. The data underline the importance of the region containing the C(-107)T polymorphism for gene expression in vivo. Differences in the affinity of the -107C and -107T polymorphic fragments for nuclear extracts have been demonstrated, and coincide with their impact on gene expression. A potential role for the transcription factor Sp1 has been demonstrated, which is consistent with the disruption of an Sp1 recognition sequence by the -107 polymorphism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12639220      PMCID: PMC1223427          DOI: 10.1042/BJ20021670

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  33 in total

1.  Polymorphism in high density lipoprotein paraoxonase gene and risk of acute myocardial infarction in men: prospective nested case-control study.

Authors:  J T Salonen; R Malin; T P Tuomainen; K Nyyssönen; T A Lakka; T Lehtimäki
Journal:  BMJ       Date:  1999-08-21

2.  The Gln-Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan.

Authors:  Y L Ko; Y S Ko; S M Wang; L A Hsu; C J Chang; P H Chu; N J Cheng; W J Chen; C W Chiang; Y S Lee
Journal:  Atherosclerosis       Date:  1998-12       Impact factor: 5.162

Review 3.  High density associated enzymes: their role in vascular biology.

Authors:  M Navab; S Y Hama; G P Hough; C C Hedrick; R Sorenson; B N La Du; J A Kobashigawa; G C Fonarow; J A Berliner; H Laks; A M Fogelman
Journal:  Curr Opin Lipidol       Date:  1998-10       Impact factor: 4.776

4.  Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes.

Authors:  M C Garin; R W James; P Dussoix; H Blanché; P Passa; P Froguel; J Ruiz
Journal:  J Clin Invest       Date:  1997-01-01       Impact factor: 14.808

5.  The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns.

Authors:  M Antikainen; S Murtomäki; M Syvänne; R Pahlman; E Tahvanainen; M Jauhiainen; M H Frick; C Ehnholm
Journal:  J Clin Invest       Date:  1996-08-15       Impact factor: 14.808

6.  Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles.

Authors:  L W Castellani; M Navab; B J Van Lenten; C C Hedrick; S Y Hama; A M Goto; A M Fogelman; A J Lusis
Journal:  J Clin Invest       Date:  1997-07-15       Impact factor: 14.808

7.  Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations.

Authors:  I Leviev; R W James
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-02       Impact factor: 8.311

8.  A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese.

Authors:  T Zama; M Murata; Y Matsubara; K Kawano; N Aoki; H Yoshino; G Watanabe; K Ishikawa; Y Ikeda
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-12       Impact factor: 8.311

9.  Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes.

Authors:  M Pfohl; M Koch; M D Enderle; R Kühn; J Füllhase; K R Karsch; H U Häring
Journal:  Diabetes       Date:  1999-03       Impact factor: 9.461

10.  Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis.

Authors:  D M Shih; L Gu; Y R Xia; M Navab; W F Li; S Hama; L W Castellani; C E Furlong; L G Costa; A M Fogelman; A J Lusis
Journal:  Nature       Date:  1998-07-16       Impact factor: 49.962

View more
  37 in total

1.  Serum paraoxonase activity is associated with variants in the PON gene cluster and risk of Alzheimer disease.

Authors:  Porat M Erlich; Kathryn L Lunetta; L Adrienne Cupples; Carmela R Abraham; Robert C Green; Clinton T Baldwin; Lindsay A Farrer
Journal:  Neurobiol Aging       Date:  2010-10-27       Impact factor: 4.673

Review 2.  Human PON1, a biomarker of risk of disease and exposure.

Authors:  C E Furlong; S M Suzuki; R C Stevens; J Marsillach; R J Richter; G P Jarvik; H Checkoway; A Samii; L G Costa; A Griffith; J W Roberts; D Yearout; C P Zabetian
Journal:  Chem Biol Interact       Date:  2010-03-23       Impact factor: 5.192

Review 3.  Recent progress in the genetics and epigenetics of paraoxonase: why it is relevant to children's environmental health.

Authors:  Nina Holland; Daneida Lizarraga; Karen Huen
Journal:  Curr Opin Pediatr       Date:  2015-04       Impact factor: 2.856

Review 4.  The genetics of vascular complications in diabetes mellitus.

Authors:  Dan Farbstein; Andrew P Levy
Journal:  Cardiol Clin       Date:  2010-08       Impact factor: 2.213

5.  Methylmercury exposure, PON1 gene variants and serum paraoxonase activity in Eastern James Bay Cree adults.

Authors:  Olivia Drescher; Eric Dewailly; Caroline Diorio; Nathalie Ouellet; Elhadji Anassour Laouan Sidi; Belkacem Abdous; Beatriz Valera; Pierre Ayotte
Journal:  J Expo Sci Environ Epidemiol       Date:  2014-01-22       Impact factor: 5.563

6.  Functional implications of single nucleotide polymorphisms rs662 and rs854860 on the antioxidative activity of paraoxonase1 (PON1) in patients with rheumatoid arthritis.

Authors:  Arkaitz Mucientes; Benjamín Fernández-Gutiérrez; Eva Herranz; Luis Rodriguez-Rodriguez; Jezabel Varadé; Elena Urcelay; José Ramón Lamas
Journal:  Clin Rheumatol       Date:  2018-12-26       Impact factor: 2.980

Review 7.  The human paraoxonase gene cluster as a target in the treatment of atherosclerosis.

Authors:  Zhi-Gang She; Hou-Zao Chen; Yunfei Yan; Hongliang Li; De-Pei Liu
Journal:  Antioxid Redox Signal       Date:  2011-10-18       Impact factor: 8.401

8.  Paraoxonase 1 (PON1) status and substrate hydrolysis.

Authors:  Rebecca J Richter; Gail P Jarvik; Clement E Furlong
Journal:  Toxicol Appl Pharmacol       Date:  2008-11-13       Impact factor: 4.219

Review 9.  Pharmacogenetics of paraoxonases: a brief review.

Authors:  D I Draganov; B N La Du
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-25       Impact factor: 3.000

10.  Developmental changes in PON1 enzyme activity in young children and effects of PON1 polymorphisms.

Authors:  Karen Huen; Kim Harley; Jordan Brooks; Alan Hubbard; Asa Bradman; Brenda Eskenazi; Nina Holland
Journal:  Environ Health Perspect       Date:  2009-06-09       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.